Nucl Med Mol Imaging.
2018 Aug;52(4):247-253. 10.1007/s13139-018-0522-0.
Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer
- Affiliations
-
- 1Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea. abc2000@knu.ac.kr
- 2Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Republic of Korea.
- KMID: 2418988
- DOI: http://doi.org/10.1007/s13139-018-0522-0
Abstract
- Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Patient Preparation and Special Consideration before Radioactive Iodine Therapy
- Diagnostic and Therapeutic Approaches to Radioactive Iodine Refractory Differentiated Thyroid Cancer
- Surgical Methods for Radioiodine Refractory Thyroid Cancer
- Nasolacrimal Duct Obstruction after Radioactive Iodine Therapy for Thyroid Cancer
- Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
